ProBioGen and Saxonia BioTec to optimise new types of bioreactors for research and diagnostics

03-Dec-2004

The internationally renowned specialist for mammalian cell lines ProBioGen AG, has established a long-term collaboration with Saxonia BioTec GmbH. The objective of this collaboration is to optimise a new generation of bioreactors developed by Saxonia. These will be tested by ProBioGen for the cultivation of human tissue and for use in producing research reagents.

"ProBioGen - just great! The project management and company culture fit together perfectly, and we are securing unique know-how in the field of mammalian cell culture for our company," says Uwe Klaus, PhD, Managing Director of Saxonia BioTec. "The extensive mutual evaluation programme reflects the great synergies between both companies."

Uwe Marx, PhD, Chief Scientific Officer of ProBioGen AG: "I see a great potential for universal parallel cultivation of human micro-organ tissues in the innovative bioreactors designed by Saxonia BioTech. By using these reactors, we can stimulate relevant and meaningful drug screening tests while avoiding animal experiments at the same time."

Both companies will share the income from the various areas the technology is to be used in. Further financial details of the co-operation were not disclosed.

https://www.bionity.com/en/news/41314/probiogen-and-saxonia-biotec-to-optimise-new-types-of-bioreactors-for-research-and-diagnostics.html